JP2022538908A5 - - Google Patents
Info
- Publication number
- JP2022538908A5 JP2022538908A5 JP2022500008A JP2022500008A JP2022538908A5 JP 2022538908 A5 JP2022538908 A5 JP 2022538908A5 JP 2022500008 A JP2022500008 A JP 2022500008A JP 2022500008 A JP2022500008 A JP 2022500008A JP 2022538908 A5 JP2022538908 A5 JP 2022538908A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- cdr1
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962870644P | 2019-07-03 | 2019-07-03 | |
| US62/870,644 | 2019-07-03 | ||
| PCT/US2020/040711 WO2021003399A1 (en) | 2019-07-03 | 2020-07-02 | Anti-tissue factor antibody-drug conjugates and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538908A JP2022538908A (ja) | 2022-09-06 |
| JP2022538908A5 true JP2022538908A5 (enExample) | 2023-07-10 |
| JP7709636B2 JP7709636B2 (ja) | 2025-07-17 |
Family
ID=74100836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500008A Active JP7709636B2 (ja) | 2019-07-03 | 2020-07-02 | 抗組織因子抗体－薬物コンジュゲート及び関連方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220257789A1 (enExample) |
| EP (1) | EP3994150A4 (enExample) |
| JP (1) | JP7709636B2 (enExample) |
| KR (1) | KR20220029724A (enExample) |
| CN (1) | CN114222752B (enExample) |
| AR (1) | AR119346A1 (enExample) |
| AU (1) | AU2020299398B2 (enExample) |
| BR (1) | BR112021025720A2 (enExample) |
| CA (1) | CA3141428A1 (enExample) |
| CL (2) | CL2021003414A1 (enExample) |
| CO (1) | CO2022001083A2 (enExample) |
| CR (1) | CR20220047A (enExample) |
| DO (1) | DOP2021000268A (enExample) |
| EA (1) | EA202193309A1 (enExample) |
| EC (1) | ECSP22007981A (enExample) |
| IL (1) | IL289138A (enExample) |
| MX (1) | MX2021015974A (enExample) |
| PE (1) | PE20221004A1 (enExample) |
| PH (1) | PH12021553289A1 (enExample) |
| TW (1) | TWI879780B (enExample) |
| WO (1) | WO2021003399A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240134250A (ko) | 2018-01-04 | 2024-09-06 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| TW202342517A (zh) * | 2022-01-12 | 2023-11-01 | 美商艾康尼醫療有限責任公司 | 使用抗組織因子抗體之炎性疾病治療 |
| KR20240150773A (ko) * | 2022-02-24 | 2024-10-16 | 에보포인트 바이오사이언시스 컴퍼니 리미티드 | 항체 및 약물 접합체 및 이의 용도 |
| WO2023172951A1 (en) * | 2022-03-09 | 2023-09-14 | Exelixis, Inc. | Methods of treating solid tumors with anti-tissue factor antibody-drug conjugates |
| WO2023196869A1 (en) * | 2022-04-05 | 2023-10-12 | Atreca, Inc. | Epha2 antibodies |
| CA3266848A1 (en) * | 2022-10-19 | 2024-04-25 | Multitude Therapeutics Inc. | Antibodies, antibody-drug conjugates, preparations and uses thereof |
| CN116143929B (zh) * | 2023-02-03 | 2023-08-01 | 北京基科晟斯医药科技有限公司 | 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用 |
| CN116789837B (zh) * | 2023-03-24 | 2024-02-23 | 山西纳安生物科技股份有限公司 | 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用 |
| CN118772282A (zh) * | 2023-04-10 | 2024-10-15 | 复旦大学 | 靶向组织因子的纳米抗体及偶联物的制备方法和用途 |
| AU2024261955A1 (en) * | 2023-04-28 | 2025-10-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-tf antibody and anti-tf antibody-drug conjugate and medical use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6055404B2 (ja) * | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| ES2905569T3 (es) * | 2014-09-17 | 2022-04-11 | Zymeworks Inc | Compuestos citotóxicos y antimitóticos y métodos para utilizarlos |
| EP3991748A3 (en) * | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| SG11202000387YA (en) * | 2017-08-25 | 2020-03-30 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
| BR112020008593A2 (pt) * | 2017-11-02 | 2020-10-20 | Genmab A/S | método de tratamento de câncer cervical em um indivíduo |
| CN111727075B (zh) * | 2017-11-27 | 2024-04-05 | 普渡制药公司 | 靶向人组织因子的人源化抗体 |
| KR20240134250A (ko) * | 2018-01-04 | 2024-09-06 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| TWI841554B (zh) * | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| KR20230028492A (ko) * | 2020-06-29 | 2023-02-28 | 젠맵 에이/에스 | 항-조직 인자 항체-약물 접합체 및 암의 치료에서의 그의 용도 |
-
2020
- 2020-07-02 PE PE2021002191A patent/PE20221004A1/es unknown
- 2020-07-02 CR CR20220047A patent/CR20220047A/es unknown
- 2020-07-02 EA EA202193309A patent/EA202193309A1/ru unknown
- 2020-07-02 WO PCT/US2020/040711 patent/WO2021003399A1/en not_active Ceased
- 2020-07-02 AU AU2020299398A patent/AU2020299398B2/en active Active
- 2020-07-02 KR KR1020227003549A patent/KR20220029724A/ko active Pending
- 2020-07-02 US US17/624,541 patent/US20220257789A1/en active Pending
- 2020-07-02 MX MX2021015974A patent/MX2021015974A/es unknown
- 2020-07-02 EP EP20835557.8A patent/EP3994150A4/en active Pending
- 2020-07-02 BR BR112021025720A patent/BR112021025720A2/pt unknown
- 2020-07-02 PH PH1/2021/553289A patent/PH12021553289A1/en unknown
- 2020-07-02 CA CA3141428A patent/CA3141428A1/en active Pending
- 2020-07-02 CN CN202080054283.1A patent/CN114222752B/zh active Active
- 2020-07-02 JP JP2022500008A patent/JP7709636B2/ja active Active
- 2020-07-03 AR ARP200101887A patent/AR119346A1/es unknown
- 2020-07-03 TW TW109122635A patent/TWI879780B/zh active
-
2021
- 2021-12-19 IL IL289138A patent/IL289138A/en unknown
- 2021-12-20 CL CL2021003414A patent/CL2021003414A1/es unknown
- 2021-12-20 DO DO2021000268A patent/DOP2021000268A/es unknown
-
2022
- 2022-02-01 CO CONC2022/0001083A patent/CO2022001083A2/es unknown
- 2022-02-01 EC ECSENADI20227981A patent/ECSP22007981A/es unknown
-
2024
- 2024-10-14 CL CL2024003094A patent/CL2024003094A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11834498B2 (en) | Biparatopic FR-alpha antibodies and immunoconjugates | |
| US20230381321A1 (en) | Camptothecin conjugates | |
| JP6412114B2 (ja) | 抗体薬物コンジュゲート | |
| JP2024096335A (ja) | 親水性抗体－薬物コンジュゲート | |
| CN106938051B (zh) | 靶向于组织因子的抗体-药物偶联物 | |
| ES2895623T3 (es) | Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes | |
| DK3102606T3 (en) | ANTIBODY MEDICINAL CONJUGATES AND IMMUNTOXINES | |
| JP2022530524A5 (enExample) | ||
| TW202203978A (zh) | 電荷可變連接子 | |
| KR20170054430A (ko) | 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트 | |
| JP2023036842A (ja) | ベンゾジアゼピン誘導体の選択的スルホン化 | |
| CA2982522A1 (en) | Site-specific antibody-drug conjugates | |
| TR201910848T4 (tr) | İntraselüler olarak ayrilabi̇len bi̇r bağa sahi̇p i̇mmunokonjugatlar | |
| JP2024530368A5 (enExample) | ||
| CN106999606A (zh) | 抗体药物偶联物 | |
| CN111295201A (zh) | 抗egfr抗体药物结合物（adc）和其用途 | |
| AU2017344198A1 (en) | Medical use of anti-c met antibody-cytotoxic drug conjugate | |
| JP2026505738A (ja) | 抗体－薬物複合体及びその使用 | |
| US20200297863A1 (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
| CN115052663A (zh) | Alk5抑制剂缀合物及其用途 | |
| WO2022082066A1 (en) | Anti-cspg4 binding agents, conjugates thereof and methods of using the same | |
| RU2832083C2 (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты | |
| WO2026011073A1 (en) | Antibody drug conjugates | |
| RU2021130453A (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты |